Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, has announced the launch of the SENSORA Cardiac Disease Detection Platform. SENSORA currently features AI that objectively identifies structural murmurs, a sign of valvular heart disease, and Care Pathway Analytics software that provides downstream visibility and metrics of the patient journey through the healthcare system.
SENSORA is a cardiovascular disease detection platform that combines the latest advancements in applied machine learning with one of the most ubiquitous medical devices in the world: the stethoscope. By capturing and analyzing heart sounds and electrical signals with its digital stethoscopes, Eko has pioneered a detection platform designed to expand as the company develops applications for additional cardiac conditions.
SENSORA FDA-cleared structural murmur detection helps health systems more accurately and consistently identify valvular heart disease (VHD) in patients during a routine visit with their primary care physician. VHD is a life-threatening condition diagnosed in more than 8 million Americans. Left undetected and untreated, it can lead to heart failure, stroke, blood clots, and death.
SENSORA Care Pathway Analytics follows patients with identified structural murmurs through the care continuum, providing downstream visibility into patient flows, clinical outcomes and patient economics. Care Pathway Analytics is designed to assist with critical decision-making by identifying care gaps that can be transformed into improved operational efficiencies, including reduced delays in delivery of care, length of stay, and readmission rates, all while improving patient and physician satisfaction.
In addition to Eko's current portfolio of five FDA 510(k) cleared digital solutions, the company has two novel machine learning algorithms in development that apply electrocardiogram (ECG) and heart sound data: a low ejection fraction detection algorithm (named "ELEFT") to detect a weakened heart pump, which is present in half of heart failure patients, and an algorithm to detect and stratify pulmonary hypertension.
Click here to read the original news story.